Nordtreat Has Appointed Outi Kallio as the New CEO
The Finnish technology company Nordtreat strengthens its growth by appointing Outi Kallio as the new CEO. Her era at Nordtreat will start from the turn of 2024/2025. Outi Kallio has a wealth of experience in commercial and industrial management, having held several key positions at Teknos Group.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240902513997/en/
The Finnish technology company Nordtreat strengthens its growth by appointing Outi Kallio as the new CEO. (Photo: Business Wire)
Outi Kallio has an extensive background in sales, HR, and marketing. She also has a proven track record of leading international teams. Currently, she holds the position of Global Commercial Director at Teknos Group.
"As Nordtreat continues to grow and evolve, we are thrilled to welcome Outi Kallio as our new CEO. Her diverse experience and proven leadership skills make her the ideal candidate to lead Nordtreat into its next chapter. We believe that Outi Kallio’s strategic vision and operational expertise will drive our company forward and enhance shareholder value," says Leif Frilund, Chairman of the Board of Nordtreat.
"With over a decade of experience in the coatings industry, I have seen a growing shift towards sustainable solutions, driven by increasing customer expectations. Nordtreat's commitment to bio-based technologies and its strong ethos of responsibility provides a solid foundation for scaling Finnish sustainability expertise into an international growth story. I am excited to join this team of top professionals and look forward to contributing to our shared success," Outi Kallio says.
As Nordtreat’s CEO, Outi Kallio will succeed Aki Borgentorp, who has led the company for ten years. These years have included the development of the first truly bio-based flame retardant for wood-based materials and the growth of a worldwide market presence.
"Over the past decade, Nordtreat has built a scalable platform for the development and production of bio-based flame retardants for wood-based materials. I am convinced that under Outi Kallio’s leadership, Nordtreat will continue to innovate and expand its presence in the market and make a significant impact in the construction materials industry," says Aki Borgentorp.
"On behalf of the Nordtreat board, I’d like to express our sincere gratitude to Aki Borgentorp for his remarkable achievement in building Nordtreat from scratch into a leading provider of new sustainable flame-retardant solutions. We wish Aki the best of success in his future endeavours," Leif Frilund says.
Nordtreat has also welcomed Dr Thomas Kostka, the Head of Corporate Venturing at Altana AG, to join the board of directors starting in August 2024. Additionally, Nordtreat has appointed Sakari Saarela, a partner in the UB FIGG Fund, as a board observer. Sampsa Auvinen, who has been on Nordtreat's board since 2022, will continue as UB FIGG's representative on the board. Sampsa Auvinen is also the Chairman of the Advisory Board of UB FIGG. Altana Group, the global leader in true specialty chemicals, and the Finnish sustainability fund UB Forest Industry Green Growth Fund (UB FIGG), a growth private equity fund investing in sustainable and resource-efficient forest and bio-based industries, announced an investment in Nordtreat in June 2024.
"We are happy to welcome Thomas Kostka to the board of directors at Nordtreat. He brings us a deep understanding of the industry and strategic insights that will be invaluable as we continue to grow," says Leif Frilund.
Nordtreat is a Finnish technology company founded in 2015, specializing in the development and production of environmentally friendly, high-performance flame retardants. Utilizing bio-based raw materials, Nordtreat's products comply with the latest fire protection regulations and have been used to protect over 2000 buildings worldwide. The company's flagship technology, NORFLAM®, is designed to provide superior fire protection while maintaining environmental sustainability. Nordtreat's innovative solutions are aimed at meeting the growing global demand for safer, more sustainable construction materials. www.nordtreat.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240902513997/en/
Contacts
Leif Frilund
Chairman, Nordtreat
leif.frilund@walki.com
+358403543330
Aki Borgentorp
CEO, Nordtreat
aki.borgentorp@nordtreat.com
+358 400 366801
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 07:00:00 EET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 03:15:00 EET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 18:59:00 EET | Press release
Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through battle-tested AI Agents at enterprise scale. The new funds will accelerate the adoption of the Torq AI SOC Platform, the only end-to-end solution built on
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom